Get The Facts : AUA/SUFU Diagnosis and Treatment Of Non-Neurogenic OAB in Adults Guideline Update

CME Available: https://auau.auanet.org/node/27477 Course Director: Eric Rovner, MD Faculty: Kathleen Kobashi, MD Sandip Vasavada, MD At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various pharmacotherapies for OAB. 2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy. 3. Realize the importance of setting proper patient expectations regarding treatment of OAB and potential need for sequential and even additive therapies. 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents. 5. Discuss potential future pharmacological pathways and therapies for OAB. This educational series is supported by an independent educational grant from: Astellas